Kristian Shearsby
Partner
Kristian is a corporate lawyer specialising in the life sciences and technology sectors, providing clients with strategic legal advice on complex transactions.
Partner
Kristian is a corporate lawyer specialising in the life sciences and technology sectors, providing clients with strategic legal advice on complex transactions.
Language - English
Jurisdiction - England & Wales
Kristian is a corporate lawyer specialising in the life sciences and technology sectors. He advises companies at all stages of development, from early-stage biotech and technology companies through to listed public companies, investment funds, and banks operating within these sectors.
Kristian’s corporate practice regularly involves advising clients on their transformative transactions, including venture capital investments, joint-venture arrangements, mergers and acquisitions and public securities issues, with a focus on delivering successful outcomes within mandated deadlines.
Kristian provides commercial and pragmatic advice, leveraging his industry and transactional experience to support innovative businesses as they grow. He works closely with colleagues on complex IP, licensing, and commercial issues, ensuring clients receive expert support tailored to their needs. His international experience, particularly with cross-border transactions involving the US, adds a valuable dimension to his practice.
Clients value Kristian's dedication to forging strong, long-lasting relationships and his commitment to helping them overcome challenges and seize opportunities. His work with leading life sciences and technology companies underscores his reputation as a trusted guide in these dynamic and evolving sectors.
Acquisition of UK biotech
Acted for Dr. Falk Pharma, a German multi-national pharmaceutical company, on its successful acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company spun out from the University of Edinburgh focusing on the development of novel treatments for patients suffering from acute and chronic inflammatory diseases.
Sale of wind services business
Advised Inspirit Capital on the sale of portfolio company CWind Limited, a market leader in offshore wind services, to All Energies Services Group (AES Group), a leading provider of sustainable energy solutions.
Acquisition of cleantech businesses
Advised SKion Water on multiple transactions including its acquisition of the business and assets of water technology company Doosan Enpure and its Series A investment in a university spin-out focussed on the development of advanced microfluidic sensor technology.
Biotech sale
Advised the majority shareholder on the sale of a biotechnology company focussed on the development of novel antibody therapeutics, including the roll-up of an equity interest into the acquiring entity and the spin-out of certain excluded IP into a Newco.
Investment for biotech business
Advised a German venture backed biotechnology company focused on delivering targeted therapies for patients with autoimmune and immune-driven diseases, on its Series C follow-on financing, undertaken by way of a convertible loan.
Investment into fintech business
Advised a UK-based investment firm, in connection with its syndicate leading role, on a £30 million A2 share financing, for a leading provider of consumer-facing digital wallets and smart account technology and the implementation of certain related secondary share sales.
Investment for cleantech business
Investment into semiconductor business
Advised Archean Chemical Industries on its subscription for and acquisition of shares in Clas-sic Wafer Fab Limited, a dedicated silicon carbide wafer foundry, together with an associated debt investment.
Biotech joint-venture
Advised AIM-listed life sciences business Horizon Discovery on the establishment of a joint venture vehicle to progress the development of an immunotherapeutic technology platform for the treatment of cancers.
Life sciences IPO
Advised a company focussed on the design, manufacture and supply of application specific synthetic DNA, on its transfer from Germany to the UK and admission to trading on the AIM market of the London Stock Exchange.
